Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Antihypertensive and renoprotective effects of trandolapril/verapamil combination: a meta-analysis of randomized controlled trials

Abstract

Both trandolapril and verapamil are effective and widely used antihypertensive agents. The aim of this study was to estimate the efficacy and tolerability of trandolapril/verapamil (Tr/Ve) combination for blood pressure control and renoprotection. PubMed, EMBASE and Cochrane Library were searched for relevant studies. A meta-analysis of all randomized controlled trials (RCTs) meeting the criteria was performed. Twelve RCTs were ultimately included out of 62 studies. (1) Combination versus trandolapril: a greater diastolic blood pressure (DBP) reduction (weighted mean difference (WMD): 3.71, 95% confidence interval (CI): 1.84–5.57); a greater reduction in albuminuria (WMD: 136.77, 95% CI: 12.44–261.09). There were no differences in reduction in systolic blood pressure (SBP), blood pressure response rate or proteinuria. (2) Combination versus verapamil: a greater SBP reduction (WMD: 6.14, 95% CI: 3.59–8.70); a greater DBP reduction (WMD: 2.49, 95% CI: 0.81–4.17); a greater reduction in proteinuria (standardized mean difference: 0.84, 95% CI: 0.22–1.45); a greater reduction in albuminuria (WMD: 255.00, 95% CI: 119.26–390.74). (3) Incidence of all-cause adverse events (AEs) was comparable between combination and monotherapy. The present meta-analysis indicates that Tr/Ve combination provides a superior blood pressure control and a favourable renoprotective effect without an increase of overall AEs than verapamil monotherapy. The combination also shows a slight advantage over trandolapril monotherapy by reducing DBP and albuminuria to a greater extent.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Purchase on Springer Link

Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Whitworth JA . 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21 (11): 1983–1992.

    Article  Google Scholar 

  2. Chobanian AV, Bakris GL, Black HR . The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 report. Hypertension 2003; 42: 1206.

    Article  CAS  Google Scholar 

  3. Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A . Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004; 65 (6): 1991–2002.

    Article  CAS  Google Scholar 

  4. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17 (1): 1–12.

    Article  CAS  Google Scholar 

  5. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009].

  6. Bakris GL, Weir MR, DeQuattro V, McMahon FG . Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54 (4): 1283–1289.

    Article  CAS  Google Scholar 

  7. DeQuattro V, Lee D . Fixed-dose combination therapy with trandolapril and verapamil SR is effective in primary hypertension. Trandolapril Study Group. Am J Hypertens 1997; 10 (7 Part 2): 138S–145S.

    Article  CAS  Google Scholar 

  8. Karlberg BE, Andrup M, Oden A . Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Swedish TARKA trialists. Blood Press 2000; 9 (2–3): 140–145.

    Article  CAS  Google Scholar 

  9. Messerli F, Frishman WH, Elliott WJ . Effects of verapamil and trandolapril in the treatment of hypertension. Trandolapril Study Group. Am J Hypertens 1998; 11 (3 Part 1): 322–327.

    Article  CAS  Google Scholar 

  10. PROCOPA Study Group. Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomized double-blind trial. J Hypertens 2002; 20 (4): 729–737.

    Article  Google Scholar 

  11. Rubio-Guerra AF, Vargas-Robles H, Vargas-Ayala G, Rodriguez-Lopez L, Escalante-Acosta BA . The effect of trandolapril and its fixed-dose combination with verapamil on circulating adhesion molecules levels in hypertensive patients with type 2 diabetes. Clin Exp Hypertens 2008; 30 (7): 682–688.

    Article  CAS  Google Scholar 

  12. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351 (19): 1941–1951.

    Article  CAS  Google Scholar 

  13. Ruilope LM, Usan L, Segura J, Bakris GL . Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResion Arterial en DIabeticos tipo Dos) study. J Hypertens 2004; 22 (1): 217–222.

    Article  CAS  Google Scholar 

  14. Scholze J, Zilles P, Compagnone D . Verapamil SR and trandolapril combination therapy in hypertension—a clinical trial of factorial design. German Hypertension Study Group. Br J Clin Pharmacol 1998; 45 (5): 491–495.

    Article  CAS  Google Scholar 

  15. Topouchian J, Asmar R, Sayegh F, Rudnicki A, Benetos A, Bacri AM et al. Changes in arterial structure and function under trandolapril-verapamil combination in hypertension. Stroke 1999; 30 (5): 1056–1064.

    Article  CAS  Google Scholar 

  16. Veratran Group. Effects of verapamil SR, trandolapril, and their fixed combination on 24-h blood pressure: the Veratran Study. Am J Hypertens 1997; 10 (5 Part 1): 492–499.

    Google Scholar 

  17. Versari D, Virdis A, Ghiadoni L, Daghini E, Duranti E, Masi S et al. Effect of verapamil, trandolapril and their combination on vascular function and structure in essential hypertensive patients. Atherosclerosis 2009; 205 (1): 214–220.

    Article  CAS  Google Scholar 

  18. Bakris GL, Ritz E . The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. J Clin Hypertens (Greenwich) 2009; 11 (3): 144–147.

    Article  Google Scholar 

  19. Rubio-Guerra AF, Lozano-Nuevo JJ, Vargas-Ayala G, Rodriguez-Lopez L, Ramos-Brizuela LM, Escalante-Acosta BA . Efficacy of a fixed-dose combination of trandolapril-verapamil in obese hypertensive patients resistant to monotherapy. Clin Exp Hypertens 2006; 28 (7): 619–624.

    Article  CAS  Google Scholar 

  20. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D . Reduction of proteinuria by angiotensin converting enzyme inhibition. Kidney Int 1987; 32 (1): 78–83.

    Article  CAS  Google Scholar 

  21. Smith AC, Toto R, Bakris GL . Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 1998; 54 (3): 889–896.

    Article  CAS  Google Scholar 

  22. Tarif N, Bakris GL . Preservation of renal function: the spectrum of effects by calcium-channel blockers. Nephrol Dial Transplant 1997; 12 (11): 2244–2250.

    Article  CAS  Google Scholar 

  23. Michelle A, Faulkner DEH . Fixed-dose combination antihypertensive therapy with trandolapril/verapamil: a meta-analytic comparison against monotherapy. Am J Hypertens 2004; 17 (5 Suppl1): S105.

    Google Scholar 

  24. Quinones-Galvan A, Pucciarelli A, Ciociaro D, Masoni A, Franzoni F, Natali A et al. Metabolic effects of combined antihypertensive treatment in patients with essential hypertension. J Cardiovasc Pharmacol 2002; 40 (6): 916–921.

    Article  CAS  Google Scholar 

  25. Fernandez R, Puig JG, Rodriguez-Perez JC, Garrido J, Redon J . Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. J Hum Hypertens 2001; 15 (12): 849–856.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to X-Y Shi.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zou, Z., Xu, FY., Wang, L. et al. Antihypertensive and renoprotective effects of trandolapril/verapamil combination: a meta-analysis of randomized controlled trials. J Hum Hypertens 25, 203–210 (2011). https://doi.org/10.1038/jhh.2010.60

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jhh.2010.60

Keywords

This article is cited by

Search

Quick links